Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356804 | 0.97 | HTR2C (0.47) | GAATDP1HTR2CHTR2BTAS1R3 | |
| SCHEMBL17356806 | 0.89 | HTR2C (0.50) | GAATDP1HTR2CHTR2BPNMT | |
| SCHEMBL24005938 | 0.85 | HTR2C (0.40) | GAATDP1HTR2CHTR2BTAS1R3 | |
| SCHEMBL17356801 | 0.84 | HTR2C (0.49) | GAATDP1HTR2CHTR2BTAS1R3 | |
| SCHEMBL12875533 | 0.82 | HTR2C (0.57) | GAATDP1HTR2CHTR2BPNMT | |
| SCHEMBL31172489 | 0.82 | HTR2C (0.57) | GAATDP1HTR2CHTR2BPNMT | |
| Ammonia Solution, Strong SCHEMBL267014 | 0.80 | HTR2C (0.56) | GAATDP1HTR2CHTR2BPNMT | |
| SCHEMBL21451906 | 0.79 | GAA (0.55) | GAATDP1HTR2CHTR2BPNMT | |
| SCHEMBL17356796 | 0.78 | HTR2C (0.43) | GAATDP1HTR2CHTR2BPNMT | |
| SCHEMBL17356809 | 0.77 | PNMT (0.46) | GAATDP1HTR2CHTR2BTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313792-A1 | METHOD FOR PRODUCING POLAR GROUP-CONTAINING OLEFIN POLYMER | THE UNIVERSITY OF TOKYO (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9499644-B2 | Production method of polar group-containing olefin polymers | SHOWA DENKO K.K. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150368376-A1 | PRODUCTION METHOD OF POLAR GROUP-CONTAINING OLEFIN POLYMERS | SHOWA DENKO K.K. (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368376-A1 | PRODUCTION METHOD OF POLAR GROUP-CONTAINING OLEFIN POLYMERS | OR10J3, OPRM1, ORC3 | GAA 4719/4885TDP1 4736/4885HTR2C 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.